O

OCX: OncoCyte Corp.

Stock

About

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Website
www.oncocyte.com
Year Founded
2009
Employees
43
Sector
Health Care
HQ Location
Irvine, CA

Current Value

$3.08

1 Year Return

$0.23
8.07%
Created with Highcharts 11.4.829 Apr27 May24 Jun22 Jul19 Aug16 Sep14 Oct11 Nov9 Dec6 Jan3 Feb3 Mar31 Mar$1$2$3$4$5

Key Details

Market Cap

$87.51M

P/E Ratio

-0.7

1Y Stock Return

2.68%

1Y Revenue Growth

25.15%

Dividend Yield

0.00%

Price to Book

-4.4

Strategies that include OCX

Create your own
strategy with

OCX
Three dimensional double logo

Stock's related to OCX

The stocks that are correlated to OCX - OncoCyte Corp. are ATEX, CELC, GDS, SEG, OCUL

Name
Correlation
Market Cap
Return % (1 Year)
Div Yield %
A
ATEXAnterix, Inc.
24.92%$680.28M+11.04%0.00%
C
CELCCelcuity, Inc.
24.33%$375.38M-51.35%0.00%
G
GDSGDS Holdings Ltd.
24.15%$4.79B+262.37%0.00%
S
SEGSeaport Entertainment Group, Inc.
23.01%$272.60M-16.63%0.00%
O
OCULOcular Therapeutix, Inc.
22.36%$1.17B-15.65%0.00%
N
NSPInsperity, Inc.
21.98%$3.32B-17.00%2.70%
Z
ZTSZoetis, Inc.
21.35%$73.73B-1.42%1.09%
G
GENIGenius Sports Ltd.
20.96%$2.40B+79.71%0.00%
H
HOUSAnywhere Real Estate, Inc.
20.48%$372.28M-44.22%0.00%
S
SAICScience Applications International Corp.
20.27%$5.36B-13.84%1.32%
A
ATNIATN International, Inc.
19.17%$314.42M-32.90%4.75%
V
VHCVirnetX Holding Corp.
19.14%$31.32M+18.43%0.00%
O
OLPXOlaplex Holdings, Inc.
19.01%$844.07M-34.54%0.00%
C
CLLSCellectis SA
18.95%$89.40M-51.18%0.00%
T
TRSTriMas Corp.
18.83%$950.86M-11.78%0.68%
E
EIXEdison International
18.83%$22.69B-16.35%4.04%
S
SEATVivid Seats, Inc.
18.79%$392.78M-50.83%0.00%
A
ACCOACCO Brands Corp.
18.54%$389.17M-22.84%7.11%
L
LANDGladstone Land Corp.
18.50%$380.66M-19.63%5.33%
O
OFLXOmega Flex, Inc.
18.45%$351.08M-51.76%3.88%

ETF's related to OCX

The ETFs that are correlated to OCX - OncoCyte Corp. are VRIG, RSPA, BBH, XBI, SRVR

Name
Correlation
AUM
Expense Ratio
V
VRIGInvesco Variable Rate Investment Grade ETF
16.50%$1.44B0.3%
R
RSPATraded Fund Trust Invesco S&P 500 Equal Weight Income Advantage ETF
15.84%$290.25M0%
B
BBHVanEck Biotech ETF
15.81%$368.79M0.35%
X
XBISPDR Biotech ETF
15.30%$5.33B0.35%
S
SRVRPacer Data & Infrastructure Real Estate ETF
15.10%$392.61M0.55%
I
IHAKiShares Cybersecurity and Tech ETF
15.04%$910.29M0.47%
F
FLTRVanEck IG Floating Rate ETF
14.97%$2.42B0.14%
I
IBBiShares Biotechnology ETF
14.46%$5.92B0.45%
F
FLRNSPDR Bloomberg Investment Grade Floating Rate ETF
14.22%$2.82B0.15%
X
XBILUS Treasury 6 Month Bill ETF
13.91%$708.45M0.15%
S
SRETGlobal X SuperDividend REIT ETF
13.31%$186.24M0.59%
U
UNGUnited States Natural Gas Fund
13.12%$434.44M1.06%
B
BETZRoundhill Sports Betting & iGaming ETF
12.87%$67.68M0.75%
E
EPHEiShares MSCI Philippines ETF
12.83%$93.97M0.59%
I
ICSHiShares Ultra Short Term Bond Active ETF
12.66%$5.66B0.08%
M
MOATVanEck Morningstar Wide Moat ETF
12.53%$13.43B0.47%
P
PTHInvesco Dorsey Wright Healthcare Momentum ETF
12.20%$110.42M0.6%
G
GNOMGlobal X Genomics & Biotechnology ETF
12.06%$53.29M0.5%
V
VRPInvesco Variable Rate Preferred ETF
11.92%$2.04B0.5%
C
CPRJCalamos Russell 2000 Structured Alt Protection ETF July
11.85%$48.46M0.69%

News

Finnhub

Corrected Transcript Total Pages: 12 CORPORATE PARTICIPANTS Joshua Riggs Ekkehard Schütz ...

SeekingAlpha

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ETCompany ParticipantsGabby Woody - Executive Assistant, HR...

SeekingAlpha

The following slide deck was published by OncoCyte Corporation in conjunction with their 2024 Q4 earnings call.

Finnhub

IRVINE, Calif. — IRVINE, Calif. — OncoCyte Corp. on Monday reported a loss of $33.5 million in its fourth quarter. The Irvine, California-based company said it had a loss of $1.93 per share....

Finnhub

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million ...

Finnhub

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded...

Disclaimer

Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.

Zero expense ratio
index investing

Company

Resources

Popular ETFs

ETF Comparisons

© Double Finance, 2024

Double is a registered investment adviser with the US Securities and Exchange Commission (SEC). While such registration does not imply a certain level of skill, it does require us to follow federal regulations that protect you, the investor. By law, we must provide investment advice that is in the best interest of our client. Please refer to Double's Form CRS for important additional information.

The publicly available portions of the Platform (i.e., the sections of the Platform that are available to individuals who are not party to a Client Agreement - including double.finance) are provided for educational purposes only and are not intended to provide legal, tax, or financial planning advice. To the extent that any of the content published on publicly available portions of the Platform may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Nothing on the publicly available portions of the Platform should be construed as a solicitation or offer, or recommendation, to buy or sell any security. All charts, figures, and graphs on the publicly available websites are for illustrative purposes only. Before investing, you should consider whether any investment, investment strategy, security, other asset, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You are also encouraged to consult your legal, tax, or investment professional regarding your specific situation. Registration does not imply a certain level of skill or training.

Investing involves risk. The value of your investment will fluctuate, and you may gain or lose money.

The contents of the Platform may contain forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates, and projections about the financial industry, the economy, or Global Predictions itself. Forward-looking statements are not guarantees of the underlying expected actions or future performance and future results may differ significantly from those anticipated by the forward-looking statements. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements.

¹ Data as of July 2024.

² Availability of tax loss harvesting depends on portfolio diversity.

³ As of November 8, 2024. The optional Cash Sweep program takes the cash sitting in your brokerage account and moves it to an FDIC-insured interest-earning deposit account. The current yield is 1.0%, rates subject to change at any time. The cash sweep program is made available in coordination with Apex Clearing Corporation. Please read the Important Disclosures for more information.

⁴ This analysis calculator tool is for illustrative purposes only and is not financial advice. We do not guarantee the accuracy of the results or their relevance to your particular circumstances. This calculator uses hypothetical historical data and does not take into account the effect of taxes on a taxable account. Hypothetical historical data is no guarantee of future performance and this calculator is not intended to predict actual performance. The input of different time periods, amounts, and fees will vary calculator results. Average ETF fee is based on the AUM weighted average of US ETFs as of September 2024, see more information. Note that you can purchase ETFs through Double, which may incur additional fees.

Full pricing details along with an FAQ can be found here

Data displayed in charts and graphics above are for illustrative purposes only and do not reflect actual investment results and are not a guarantee of future results.

By using double.finance, you accept our and . Double is only available to US residents.

See Double Finance Form ADV Part IIA for additional information. Double does not guarantee that the results of its advice, recommendations, or the objectives of its direct index or cash management strategies will be achieved. We make no assurance that the investment process will consistently lead to successful investing. Before you invest, you should carefully review and consider your investment objectives as well as the risks, charges, and expenses of the underlying securities. There is at least a $1,000 account minimum required to participate in Double's strategies, although some strategies may have higher minimums.

Double does not provide tax, or legal advice. Double's website, brokerage, and advisory services are not intended for persons of any jurisdiction where Double is not authorized to do business. Tax savings will vary from client to client due to many factors including market conditions, tax characteristics of securities, client-imposed investment restrictions, client tax rate or status, and changes in tax regulations.

0% Expense Ratios with TLH

We offer over 50 indexes with zero expense ratios.

Registration will take about 10 seconds